Eli Lilly (LLY): Lilly targets amylin pathway for next-gen obesity drug combinations
Eli Lilly announced its focus on the amylin pathway for next-generation obesity drug combinations on October 5. The stock initially did not react but has since gained significantly, rising 0.8 sigma on October 6 and 1.6 sigma on October 7, indicating growing investor enthusiasm.
Move beyond the market by session
In typical days (σ): the move of LLY beyond its usual link to QQQ. Darker bars are days with an event of the storyline; R marks a report window.
Chronology
Events of the storyline in the order they reached our feed, New York time. An event is one fact; its first headline and up to three other reports are shown.
Evening assessments
Every evening at 22:00 UTC while the storyline had news in the last three days. The model saw only the events that had arrived by then and the daily moves of the stock beyond the market.
20%−10 ▲ Announcement of a clinical trial initiation or partnership for an amylin-based obesity drug
Eli Lilly announced its focus on the amylin pathway for next-generation obesity drug combinations on October 5. The stock initially did not react but has since gained significantly, rising 0.8 sigma on October 6 and 1.6 sigma on October 7, indicating growing investor enthusiasm.
Why: The stock has already moved on the strategy news, but a concrete development like a trial start could provide further upside. · size: medium · priced in: partly
What the model was given · DeepSeek-V4-Flash, thinking high · a2
Company: LLY (Eli Lilly). Now: 2026-10-07 22:00 UTC (Wednesday). Storyline: Lilly targets amylin pathway for next-gen obesity drug combinations Chronology (UTC): - 10-05 13:03 Eli Lilly Targets Amylin Pathway to Unlock Next Generation Obesity Drug Combinations Stock move beyond the market by session, in typical days (sigma): 09-30 -1.4, 10-01 -0.4, 10-02 -0.4, 10-05 +0.0, 10-06 +0.8, 10-07 +1.6
30%+20 • —
Eli Lilly announced on October 5 that it is targeting the amylin pathway for next-generation obesity drug combinations, but the stock showed minimal reaction (0.0 sigma on the day, +0.8 sigma the next). The market awaits more concrete details such as clinical trial plans or partnerships.
Why: The initial announcement lacked specific milestones or timelines, so the probability of a decisive catalyst within five trading days is moderate and the direction is uncertain. · size: medium · priced in: little
What the model was given · DeepSeek-V4-Flash, thinking high · a2
Company: LLY (Eli Lilly). Now: 2026-10-06 22:00 UTC (Tuesday). Storyline: Lilly targets amylin pathway for next-gen obesity drug combinations Chronology (UTC): - 10-05 13:03 Eli Lilly Targets Amylin Pathway to Unlock Next Generation Obesity Drug Combinations Stock move beyond the market by session, in typical days (sigma): 09-29 -0.0, 09-30 -1.4, 10-01 -0.4, 10-02 -0.4, 10-05 +0.0, 10-06 +0.8
10% • —
Eli Lilly announced it is targeting the amylin pathway for next-generation obesity drug combinations. The stock showed no significant move on the news, indicating the market views this as a long-term strategic direction without immediate catalysts. No specific near-term milestones or events are known.
Why: The stock did not react to the announcement, suggesting it is not seen as a near-term catalyst, so any upcoming step is unlikely to be a major surprise or have a significant impact within 5 days. · size: small: under one typical day · priced in: little
What the model was given · DeepSeek-V4-Flash, thinking high · a2
Company: LLY (Eli Lilly). Now: 2026-10-05 22:00 UTC (Monday). Storyline: Lilly targets amylin pathway for next-gen obesity drug combinations Chronology (UTC): - 10-05 13:03 Eli Lilly Targets Amylin Pathway to Unlock Next Generation Obesity Drug Combinations Stock move beyond the market by session, in typical days (sigma): 09-28 +0.1, 09-29 -0.0, 09-30 -1.4, 10-01 -0.4, 10-02 -0.4, 10-05 +0.0
How the model built the storyline
For each event the model was shown the company’s active storylines and chose: continue one, start a new one or treat the event as a one-off.
-
New storyline · Eli Lilly Targets Amylin Pathway to Unlock Next Generation Obesity Drug Combinations
Question and answer · DeepSeek-V4-Flash, thinking high · s2
Company: LLY (Eli Lilly) New event (10-05 13:03 UTC): Eli Lilly Targets Amylin Pathway to Unlock Next Generation Obesity Drug Combinations Storylines: 1. Gate Bioscience collaboration expansion for difficult-to-drug proteins first (10-05 12:04): Gate Bioscience Expands Collaboration and License Agreement with Lilly to Target Difficult-to-Drug Proteins 2. Foundayo demonstrates cardiovascular safety in large type 2 diabetes trial first (09-30 22:02): Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study latest (10-02 22:46): Eli Lilly’s Foundayo delivers diabetes surprise in late-stage study 3. Jaypirca FDA approval expansion for CLL/SLL first (10-02 19:07): Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL 4. Lilly takes over Milan facility in obesity battle with Novo first (10-02 08:20): Lilly Upstages Novo in Fresh Obesity Battle by Taking Over Milan 5. Lilly dispute with German health policy first (10-02 07:01): “My Trust Is Destroyed” Eli Lilly Boss Settles Accounts With German Health Policy - HB 6. Lilly exits Foghorn collaboration on cancer drug first (10-01 12:08): Foghorn plunges as Lilly exits collaboration latest (10-01 16:21): Foghorn Therapeutics Pivots Pipeline after Ending Eli Lilly Deal 7. EloraTZP Phase 2 success in obesity and type 2 diabetes first (09-30 14:15): Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes latest (09-30 14:21): Experimental Lilly combination drug tops Zepbound in weight-loss trial 8. EBGLYSS Phase 3b success in hand and foot atopic dermatitis first (09-30 12:05): New Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis 9. Retatrutide phase 3 results show substantial weight loss and A1C reduction first (09-29 22:02): Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes latest (09-30 00:12): ELI LILLY SAYS THE TRIPLE AGONIST ALSO REDUCED A1C IN PEOPLE WITH OBESITY AND TYPE 2 DIABETES, WITH A BIOLOGICS LICENCE APPLICATION PLANNED FOR Q1 2027. 10. Foundayo shows superiority over oral semaglutide in diabetes analysis first (09-29 07:01): Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison latest (09-29 16:14): Lilly Stock Drops Lowwer Foundayo Claims an Oral Edge 11. Zepbound shows greater weight loss than Wegovy in indirect comparison first (09-29 11:02): Lilly's Zepbound (tirzepatide 10 mg and 15 mg) was associated with more weight loss than Wegovy HD (semaglutide injection 7.2 mg) in a new indirect treatment comparison 12. Novo Nordisk trial results show cardiovascular edge over Lilly's tirzepatide first (09-28 18:45): Novo Nordisk Just Beat Lilly in a Trial. Is the Comeback Finally Taking Shape? → {"story": 0, "title": "Lilly targets amylin pathway for next-gen obesity drug combinations"}